COMPANY

CG Oncology

HQ: Dallas, TX source · cgoncology.com ↗

Location: Dallas, TX · source · Oct 12, 2026

Profile checked Oct 10, 2026

Keywords: Non-Muscle Invasive Bladder Cancer Bladder Cancer Urothelial Carcinoma Urologic Cancer High-Risk Non-Muscle-Invasive Bladder Cancer Non Muscle Invasive Transitional Cell Carcinoma Carcinoma in Situ Cretostimogene Grenadenorepvec CG0070 oncolytic adenovirus expressing GMCSF CG0070 Adenovirus Vector

$238.0MRaised (2 yrs)8Trials (company is sponsor)

Timeline

Dec 16, 2024 Raise Follow-on offering: $238M (total, as published), announced Dec 16, 2024. Source: company release on GlobeNewswire. source ↗
Sep 16, 2024 Trial start 2: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC source ↗
Dec 14, 2023 Trial start Phase 3: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT source ↗
Dec 8, 2020 Trial start Phase 2: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin source ↗
Oct 27, 2020 Trial start Phase 3: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin source ↗
Jun 2, 2015 Trial start Phase 2: Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure source ↗
2014-03 Trial start Phase 2: Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer source ↗
2014-03 Trial start Phase 2/Phase 3: Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 3 · A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT · NCT06111235
Mar 31, 2027 (ESTIMATED) · 2 · Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC · NCT06567743
Jun 16, 2030 (ESTIMATED) · Phase 3 · Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin · NCT04452591

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $238.0M. Last 2 years.

Dec 16, 2024 Follow-on offering: $238M (total, as published), announced Dec 16, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06443944	An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG	Not listed	Available	Not listed	Not listed
NCT06567743	Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC	2	Recruiting	Sep 16, 2024	Mar 31, 2027 (estimated)
NCT04452591	Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Phase 3	Active, not recruiting	Oct 27, 2020	Jun 16, 2030 (estimated)
NCT06111235	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Phase 3	Active, not recruiting	Dec 14, 2023	2026-11 (estimated)
NCT02143804	Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer	Phase 2	Withdrawn	2014-03	2015-03 (actual)
NCT04387461	Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin	Phase 2	Completed	Dec 8, 2020	Mar 7, 2023 (actual)
NCT01438112	Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer	Phase 2/Phase 3	Terminated	2014-03	2016-06 (actual)
NCT02365818	Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure	Phase 2	Completed	Jun 2, 2015	2018-08 (actual)